New York Eye and Ear Infirmary of Mount Sinai is located at East 14th Street and Second Avenue in lower Manhattan, New York City.

During the past decade, New York Eye and Ear Infirmary conducted 45 clinical trials. In the 10-year time frame, 45 clinical trials started and 31 clinical trials were completed, i.e. on average, 68.9% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 18 clinical trials were completed. i.e. 90% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New York Eye and Ear Infirmary" #1 sponsor was "The New York Eye & Ear Infirmary" with 16 trials, followed by "Jaeb Center for Health Research" with 11 trials sponsored, "Lux Biosciences, Inc." with 5 trials sponsored, "Icahn School of Medicine at Mount Sinai" with 4 trials sponsored and "Boehringer Ingelheim" with 4 trials sponsored. Other sponsors include 56 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New York Eye and Ear Infirmary" #1 collaborator was "National Eye Institute (NEI)" with 21 trials as a collaborator, "Genentech, Inc." with 5 trials as a collaborator, "Allergan" with 4 trials as a collaborator, "National Institutes of Health (NIH)" with 4 trials as a collaborator and "Regeneron Pharmaceuticals" with 4 trials as a collaborator. Other collaborators include 37 different institutions and companies that were collaborators in the rest 38 trials.

According to Clinical.Site data, the most researched conditions in "New York Eye and Ear Infirmary" are "Glaucoma" (9 trials), "Diabetic Macular Edema" (7 trials), "Diabetic Retinopathy" (7 trials), "Age Related Macular Degeneration" (4 trials) and "Geographic Atrophy" (4 trials). Many other conditions were trialed in "New York Eye and Ear Infirmary" in a lesser frequency.

Most popular intervention types in "New York Eye and Ear Infirmary" are "Drug" (59 trials), "Device" (19 trials), "Procedure" (16 trials), "Other" (15 trials) and "Behavioral" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "LX211" (3 trials), "tasimelteon" (3 trials), "Acetazolamide" (2 trials) and "Deferred aflibercept" (2 trials). Other intervention names were less common.

The vast majority of trials in "New York Eye and Ear Infirmary" are 100 trials for "All" genders.

Currently, there are 17 active trials in "New York Eye and Ear Infirmary". 2 are not yet recruiting, 9 are recruiting, 4 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 58 completed trials in New York Eye and Ear Infirmary, 1 suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in New York Eye and Ear Infirmary, 7 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 21 trials that are defined as “Not Applicable".